The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Therapeutic in vivo delivery of gene editing agents
Open accessAbstract
In vivo gene editing therapies offer the potential to treat the root causes of many genetic diseases. Realizing the promise of therapeutic in vivo gene editing requires the ability to safely and efficiently deliver gene editing agents to relevant organs and tissues in vivo. Here, we review current delivery technologies that have been used to enable therapeutic in vivo gene editing, including viral vectors, lipid nanoparticles, and virus-like particles. Since no single delivery modality is likely to be appropriate for every possible application, we compare the benefits and drawbacks of each method and highlight opportunities for future improvements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–228 of 228
AAV9 Edits Muscle Stem Cells in Normal and Dystrophic Adult Mice
Nance, M. E., Shi, R., Hakim, C. H., Wasala, N. B., Yue, Y., Pan, X., Zhang, T., Robinson, C. A., Duan, S. X., Yao, G., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.06.012 · Cited by 77
DdCBE mediates efficient and inheritable modifications in mouse mitochondrial genome
Guo, J., Chen, X., Liu, Z., Sun, H., Zhou, Y., Dai, Y., Ma, Y., He, L., Qian, X., Wang, J., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.11.016 · Cited by 77
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76
Large-Fragment Deletions Induced by Cas9 Cleavage while Not in the BEs System
Song, Y., Liu, Z., Zhang, Y., Chen, M., Sui, T., Lai, L., & Li, Z. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.06.019 · Cited by 74
Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector
Zhang, H., Bamidele, N., Liu, P., Ojelabi, O., Gao, X. D., Rodríguez, T., Cheng, H., Kelly, K. L., Watts, J. K., Xie, J., et al. (2022) · GEN Biotechnology · doi:10.1089/genbio.2022.0015 · Cited by 69
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout
Knopp, Y., Geis, F. K., Heckl, D., Horn, S., Neumann, T., Kuehle, J., Meyer, J., Fehse, B., Baum, C., Morgan, M. A., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.006 · Cited by 63
Jo, D. H., Jang, H., Cho, C. S., Han, J. H., Ryu, G., Jung, Y., Bae, S., & Kim, J. H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.021 · Cited by 63
Kwon, J. B., Ettyreddy, A. R., Vankara, A., Bohning, J. D., Devlin, G. W., Hauschka, S. D., Asokan, A., & Gersbach, C. A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.016 · Cited by 62
Development of Highly Efficient Dual‐AAV Split Adenosine Base Editor for In Vivo Gene Therapy
Chen, Y., Zhi, S., Liu, W., Wen, J., Hu, S., Cao, T., Sun, H., Li, Y., Huang, L. T., Liu, Y., et al. (2020) · Small Methods · doi:10.1002/smtd.202000309 · Cited by 57
Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation
Ferrari, S., Vavassori, V., Canarutto, D., Jacob, A., Castiello, M. C., Omer, A., & Genovese, P. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618378 · Cited by 57
Xu, Z., Yue, Y., Lai, Y., Ye, C., Qiu, J., Pintel, D. J., & Duan, D. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.896 · Cited by 55
Xiao, Y., Muhuri, M., Li, S., Qin, W., Xu, G., Luo, L., Li, J., Letizia, A. J., Wang, S. K., Chan, Y. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99052 · Cited by 53
Indiková, I., & Indik, S. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa561 · Cited by 53
Endocytosis in cellular uptake of drug delivery vectors: Molecular aspects in drug development
Kaźmierczak, Z., Szostak‐Paluch, K., Przybyło, M., Langner, M., Witkiewicz, W., Jędruchniewicz, N., & Dąbrowska, K. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115556 · Cited by 53
Geutskens, S. B., van der Eb, M. M., Plomp, A. C., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301251 · Cited by 52
Comprehensive deletion landscape of CRISPR-Cas9 identifies minimal RNA-guided DNA-binding modules
Shams, A., Higgins, S. A., Fellmann, C., Laughlin, T. G., Oakes, B. L., Lew, R., Kim, S., Lukarska, M., Arnold, M. L., Staahl, B. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25992-8 · Cited by 52
Lyu, P., Lu, Z., Cho, S.-I., Yadav, M., Yoo, K. W., Atala, A., Kim, J., & Lu, B. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0095 · Cited by 50
Fine, E. J., Appleton, C. M., White, D. E., Brown, M. T., Deshmukh, H., Kemp, M. L., & Bao, G. (2015) · Scientific Reports · doi:10.1038/srep10777 · Cited by 43
Improved Lentiviral Gene Delivery to Mouse Liver by Hydrodynamic Vector Injection through Tail Vein
Dalsgaard, T. K., Cecchi, C. R., Askou, A. L., Bak, R. O., Andersen, P. O., HOUGAARD, D. M., Jensen, T. G., Dagnæs‐Hansen, F., Mikkelsen, J. G., Corydon, T. J., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.005 · Cited by 41
Kymäläinen, H., Appelt, J. U., Giordano, F. A., Davies, A. F., Ogilvie, C. M., Ahmed, S., Laufs, S., Schmidt, M., Bode, J., Yáñez‐Muñoz, R. J., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.172 · Cited by 38
Lu, Z., Yao, X., Lyu, P., Yadav, M., Yoo, K. W., Atala, A., & Lu, B. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0106 · Cited by 37
Efficient and high-fidelity base editor with expanded PAM compatibility for cytidine dinucleotide
Liu, Z., Chen, S., Jia, Y., Shan, H., Chen, M., Song, Y., Lai, L., & Li, Z. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1775-2 · Cited by 35
In Vivo Hematopoietic Stem Cell Transduction
Richter, M., Stone, D., Miao, C. H., Humbert, O., Kiem, H., Papayannopoulou, T., & Lieber, A. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.001 · Cited by 29
Sangamo's landmark genome editing trial gets mixed reception
Sheridan, C. (2018) · Nature Biotechnology · doi:10.1038/nbt1018-907 · Cited by 29
CRISPR-derived genome editing therapies: Progress from bench to bedside
Rees, H. A., Minella, A. C., Burnett, C. A., Komor, A. C., & Gaudelli, N. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.027 · Cited by 26
Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina
Fan, L., Hung, S. S. C., Khalid, M. K. N. M., Wang, J.-H., Chrysostomou, V., Wong, V. H. Y., Singh, V., Wing, K., Tu, L., Bender, J. A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.021 · Cited by 24
Nature and Frequency of Genetic Disease
Korf, B. R., Pyeritz, R. E., & Grody, W. W. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812537-3.00003-2 · Cited by 19
Cited by
An, M., Raguram, A., Du, S. W., Banskota, S., Davis, J. R., Newby, G. A., Chen, P. Z., Palczewski, K., & Liu, D. R. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02078-y · Cited by 263
Self-citationIn vivo human T cell engineering with enveloped delivery vehicles
Hamilton, J. R., Chen, E., Perez, B. S., Sandoval Espinoza, C. R., Kang, M. H., Trinidad, M., Ngo, W., & Doudna, J. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02085-z · Cited by 256
CRISPR technologies for genome, epigenome and transcriptome editing
Villiger, L., Joung, J., Koblan, L., Weissman, J., Abudayyeh, O. O., & Gootenberg, J. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00697-6 · Cited by 256
Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice
Reichart, D., Newby, G. A., Wakimoto, H., Lun, M., Gorham, J. M., Curran, J. J., Raguram, A., DeLaughter, D. M., Conner, D. A., Marsiglia, J. D. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02190-7 · Cited by 203
Self-citationHan, E. L., Padilla, M. S., Palanki, R., Kim, D., Mrksich, K., Li, J. J., Tang, S., Yoon, I.-C., & Mitchell, M. J. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c03509 · Cited by 72
Metadata
- Authors
- Raguram, A., Banskota, S., & Liu, D. R.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 185
- Issue
- 15
- Pages
- 2806-2827
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4283836459
- Cited by
- 522
- References
- 228
- FWCI
- 27.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.